Exosomes News and Research

RSS

Thermo Fisher Scientific acquires Life Technologies

Thermo Fisher Scientific, the world leader in serving science, today announced that it has completed its acquisition of Life Technologies Corporation (NASDAQ: LIFE) for $76.13 ($76.1311786) in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of $1.5 billion in net debt. The completion of the transaction follows the receipt of all required regulatory approvals.

4 Feb 2014

Spontaneous tumorigenic transformation of human MSCs can occur during cell culture expansion

Researchers at Erasmus University Medical Center Rotterdam, The Netherlands, led by Dr. Qiuwei Pan and Dr. Luc van der Laan, have discovered that spontaneous tumorigenic transformation of human mesenchymal stem/stromal cells (MSCs) can occur during cell culture expansion, although the frequency is relatively low and often only observed after extensive passage in culture.

30 Jan 2014

Researchers reveal how genetic susceptibility plays large role in cancer risk

In laboratory experiments conducted on human cell lines at the Johns Hopkins Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by a byproduct of alcohol, called acetaldehyde.

24 Jan 2014

Salmonella infections can reduce incidence of asthma, say researchers

Researchers from Germany have identified the mechanism by which Salmonella infections can reduce the incidence of asthma in mice. The research, which appears ahead of print in the journal Infection and Immunity, opens up new avenues of research that could lead to treatments.

24 Jan 2014

Study ultimately could lead to development of screening test for diagnosing bladder cancer

Findings from a Loyola University Medical Center study ultimately could lead to tests to screen for and diagnose bladder cancer.

22 Jan 2014

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

21 Jan 2014

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Rainbow Coral Corp. is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

20 Jan 2014

Scientist receives grant to study biochemical fate of nanoemulsion-based food delivery systems in GI tract

Food scientist Hang Xiao of the University of Massachusetts Amherst recently received a four-year, $491,220 grant to study the biochemical fate of nanoemulsion-based food delivery systems in the gastrointestinal (GI) tract, hoping to re-shape them and enhance the absorption of beneficial food components encapsulated in delivery systems.

20 Jan 2014

Hope in sight for sufferers of chronic renal disease

Miss M. spends around 15 hours a week in hospital. Her renal functions are limited, and her kidneys are no longer able to filter toxins from her blood. She is a dialysis patient, forced to rely on this artificial blood purification treatment that, although essential, greatly impairs her quality of life. She has to make three trips a week to the dialysis clinic and going away for longer than a few days is almost out of the question. And Miss M. is no exception: In Germany alone, over six million people suffer from some form of chronic renal disease.

17 Jan 2014

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls.

16 Jan 2014

Research findings suggest possible blood test to identify cancer-related DNA defects

Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.

9 Jan 2014

Thermo Fisher Scientific agrees to sell three businesses to GE Healthcare for $1.06 billion

Thermo Fisher Scientific, the world leader in serving science, today announced that it has signed an agreement to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare, a unit of General Electric Company, for approximately $1.06 billion. The businesses will become part of GE Healthcare's Life Sciences division.

6 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

Most clinical trials of vitamin supplements have flawed methodology

Most large, clinical trials of vitamin supplements, including some that have concluded they are of no value or even harmful, have a flawed methodology that renders them largely useless in determining the real value of these micronutrients, a new analysis suggests.

31 Dec 2013

Researchers study health consequences of RTE proliferation that occurs in aging tissues

The genomes of organisms from humans to corn are replete with "parasitic" strands of DNA that, when not suppressed, copy themselves and spread throughout the genome, potentially affecting health. Earlier this year Brown University researchers found that these "retrotransposable elements" were increasingly able to break free of the genome's control in cultures of human cells.

27 Dec 2013

Intrexon enters into definitive agreement to acquire Medistem

Intrexon Corporation, a leader in synthetic biology, today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. a pioneer in the development of Endometrial Regenerative Cells, universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung.

21 Dec 2013

Study reveals that K-Ras gene mutations behave in ways that subvert normal mechanisms of cell death

Cells with a mutation in the gene called K-Ras—found in close to 30 percent of all cancers, but mostly those with worst prognosis, such as pancreatic cancer, colon cancer, and lung cancer—behave in ways that subvert the normal mechanisms of cell death, according to a cell-culture study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah.

20 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

Research findings point to possible new strategy for treating ALS

Amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is a devastating illness that gradually robs sufferers of muscle strength and eventually causes a lethal, full-body paralysis. The only drug available to treat the disease extends life spans by a meager three months on average.

17 Dec 2013

Cancer cells that fuse with macrophages play key role in the spread of cancer

Cancer cells that spontaneously fuse with macrophages, the immune system's healthy scavenger cells, play a key role in the metastasis, or spread of the cancer to other areas of the body, according to research to be presented Sunday, Dec. 15, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013